Group 1 - The company has received approval from the National Medical Products Administration for clinical trials of the drug JKN2301, which is a dry suspension intended for children aged 2 to 12 years with uncomplicated influenza [1][2] - JKN2301 is developed from the patented compound Marapacisavir and aims to meet the clinical needs in the treatment of influenza in children, allowing for flexible dosage adjustments based on weight [1][2] - The total research and development expenses incurred by the company for JKN2301 amount to approximately RMB 6.9453 million [2] Group 2 - Influenza poses a global public health issue, with seasonal outbreaks leading to significant health impacts; the estimated domestic terminal sales of antiviral drugs for influenza in 2024 is around RMB 4.7 billion [2]

健康元（600380）公告，公司收到国家药监局核准签发的《药物临床试验批准通知书》，批准JKN2301 干混悬剂开展临床试验。该药品适用于2至12岁以下单纯性甲型和乙型流感儿童患者，是以专利化合物 玛帕西沙韦开发的创新药，可根据儿童体重灵活调整剂量，提高儿童用药依从性。 ...